Over the Christmas period, INTEGRA Biosciences made a generous contribution of €20 thousand to promote research at the Ludwig Maximilian University of Munich (LMU). This will focus on an aggressive brain tumor known as DIPG (diffuse intrinsic ponsglioma) which is usually found in children ages five to nine.

Fortunately, the occurrence of brain tumors in children is not common, however they often come with a high mortality rate, with the two-year survival rate being 10% and just 5% for the 5-year rate.

“INTEGRA Biosciences made a generous contribution of €20 thousand to promote research at the Ludwig Maximilian University of Munich“

LMU’s DIPG Fighter research group aims to discover innovative treatment options for the pediatric tumor. The researchers already use many INTEGRA products which include their range of pipettes; the laboratory equipment supplier is excited to be able to help achieve positive solutions through research.

Dr. Alexander Beck, lead of the LMU research group said that “We are delighted to have been chosen as the recipient of this generous donation. We are dedicated to the rapid translation of drugs for pediatric brain tumors, with a particular emphasis on preclinical drug screening and testing. This donation will fund the continuation of our existing cutting-edge research projects, with the ultimate goal of identifying approved therapeutics that can be repurposed for new clinical applications.”

INTEGRA’s Marketing Comms Director, Dr Lukas Keller, commented: “We love encouraging initiatives that make the world a better place and, this year, we’ve been able to pledge 20,000 Euros to help advance the groundbreaking brain tumor research conducted at the LMU. We are excited to see how this festive contribution will be used to help children around the world with this disease.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.